<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Health Qual Life Outcomes</journal-id><journal-title>Health and Quality of Life Outcomes</journal-title><issn pub-type="epub">1477-7525</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">15777478</article-id><article-id pub-id-type="pmc">PMC555749</article-id><article-id pub-id-type="publisher-id">1477-7525-3-16</article-id><article-id pub-id-type="doi">10.1186/1477-7525-3-16</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Role of health-related quality of life measures in the routine care of people with multiple sclerosis</article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>Solari</surname><given-names>Alessandra</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>solari@istituto-besta.it</email></contrib></contrib-group><aff id="I1"><label>1</label>Epidemiology Unit, National Neurological Institute C. Besta, Via Celoria 11, 20133 Milan, Italy</aff><pub-date pub-type="collection"><year>2005</year></pub-date><pub-date pub-type="epub"><day>18</day><month>3</month><year>2005</year></pub-date><volume>3</volume><fpage>16</fpage><lpage>16</lpage><ext-link ext-link-type="uri" xlink:href="http://www.hqlo.com/content/3/1/16"/><history><date date-type="received"><day>7</day><month>2</month><year>2005</year></date><date date-type="accepted"><day>18</day><month>3</month><year>2005</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2005 Solari; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2005</copyright-year><copyright-holder>Solari; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author>
               Solari
               Alessandra
               
               solari@istituto-besta.it
            </dc:author><dc:title>
            Role of health-related quality of life measures in the routine care of people with multiple sclerosis
         </dc:title><dc:date>2005</dc:date><dcterms:bibliographicCitation>Health and Quality of Life Outcomes 3(1): 16-. (2005)</dcterms:bibliographicCitation><dc:identifier type="sici">1477-7525(2005)3:1&#x0003c;16&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1477-7525</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><p>Health-related quality of life instruments are expected to be of particular value in routine care of people with multiple sclerosis (MS), where they may facilitate the detection of disease aspects that would otherwise go unrecognised, help clinicians appreciate patient priorities particularly in terms of treatment goals, facilitate physician-patient communication, and promote shared decision-making. However, it appears that these instruments are little used routine clinical approaches to people with MS. To address this issue, I performed a bibliographic search of studies that evaluated the efficacy of generic or disease-specific health-related quality of life (HRQOL) instruments in MS clinical practice from clinicians' or patients' perspectives. I found only one cross-sectional study, which compared preferences for three instruments, and assessed acceptability in people with MS.</p><p>Reasons for lack of transfer of HRQOL measurements to clinical practice may be cultural, methodological, or practical. With regard to MS, the proliferation of instruments seems to constitute a barrier, with no particular instrument having gained wide popularity or consensus. Other barriers are lack of resources for the administration, collection and storage of the data, and inability of clinicians to score, interpret, and use HRQOL instrument to guide clinical care. It is therefore important to refine existing tools, extending clinical validation to wider contexts and cultures. More studies assessing acceptability and clinicians' and patients' preferences for different instruments are also required.</p></abstract><kwd-group><kwd>Multiple sclerosis</kwd><kwd>health-related quality of life</kwd><kwd>outcomes assessment</kwd><kwd>clinical practice</kwd></kwd-group></article-meta></front><body><sec><title>Review</title><p>Multiple sclerosis (MS) is a demyelinating disease of the central nervous system of unknown etiology and poorly understood pathogenesis. There is a north-south gradient of MS prevalence in the northern hemisphere, with highest levels (over 100 per 100,000) in northern regions [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref>]. It is a chronic disease with a modest effect on life expectancy, but a broad spectrum of consequences, of variable severity, on physical and psychological characteristics, that vary between individuals and within individuals over time. The disease typically strikes women (2:1) in their peak years of career development and family life; commonly there are exacerbations and remissions followed by progression whose rate and extent vary [<xref ref-type="bibr" rid="B3">3</xref>]. There is also a benign form of MS, characterised by few relapses, long periods of remission, and mild activity limitations over the long term [<xref ref-type="bibr" rid="B4">4</xref>]. The available treatments have at best a modest benefit on the course of the disease [<xref ref-type="bibr" rid="B5">5</xref>].</p><sec><title>Health-related quality of life measures</title><p>Interest in measuring outcomes in MS has increased markedly over the past 20 years. Standardised instruments have been developed, the most-used being the Expanded Disability Status Scale (EDSS) [<xref ref-type="bibr" rid="B6">6</xref>] which is a mixed impairment/activity limitations scale based on neurological examination of eight functional systems, plus ambulation/mobility status. Despite major limitations &#x02013; bias towards locomotor function, variable sensitivity to change according to scale score, and suboptimal inter-rater reliability &#x02013; the EDSS is widely-used by researchers and clinicians because its scores are readily understood by all.</p><p>More recently, the importance of MS outcome assessment from the perspective of the person with the disease has been recognised [<xref ref-type="bibr" rid="B7">7</xref>]. After 1992, the number of publications on health-related quality of life (HRQOL) increased steadily, as did those employing MS-specific instruments (see Figure). Generic instruments were applied to MS [<xref ref-type="bibr" rid="B7">7</xref>-<xref ref-type="bibr" rid="B12">12</xref>], and disease-specific instruments were devised and validated [<xref ref-type="bibr" rid="B13">13</xref>-<xref ref-type="bibr" rid="B24">24</xref>]. The seven available MS-specific HRQOL instruments are listed in the Table <xref ref-type="table" rid="T1">1</xref>; all were published between 1995 and 2001. Three consist of a generic module (SF-36 [<xref ref-type="bibr" rid="B13">13</xref>,<xref ref-type="bibr" rid="B15">15</xref>] or FACT-G [<xref ref-type="bibr" rid="B14">14</xref>]) plus an MS-specific module. In most cases people with MS participated in their development [<xref ref-type="bibr" rid="B13">13</xref>,<xref ref-type="bibr" rid="B16">16</xref>]. Except for the MS Quality of Life 54 (MSQOL-54), which has been translated into several languages [<xref ref-type="bibr" rid="B13">13</xref>,<xref ref-type="bibr" rid="B20">20</xref>-<xref ref-type="bibr" rid="B23">23</xref>], and the Functional Assessment of MS (FAMS), which is also available in Portuguese [<xref ref-type="bibr" rid="B24">24</xref>], these questionnaires are available only their original versions. Aspects of responsiveness were evaluated in four of the seven instruments, but in general sensitivity to change has been insufficiently investigated [<xref ref-type="bibr" rid="B18">18</xref>,<xref ref-type="bibr" rid="B25">25</xref>-<xref ref-type="bibr" rid="B28">28</xref>]</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Characteristics of MS-specific HRQOL questionnaires</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="center"><bold>MSQOL-54</bold></td><td align="center"><bold>FAMS</bold></td><td align="center"><bold>MSQLI</bold></td><td align="center"><bold>RAYS</bold></td><td align="center"><bold>HAQUAMS</bold></td><td align="center"><bold>MSIS-29</bold></td><td align="center"><bold>LMSQoL</bold></td></tr></thead><tbody><tr><td align="left">Publication year</td><td align="center">1995</td><td align="center">1996</td><td align="center">1999</td><td align="center">2000</td><td align="center">2001</td><td align="center">2001</td><td align="center">2001</td></tr><tr><td align="left">Generic module</td><td align="center">SF-36 (36 items)</td><td align="center">FACT-G (28 items)</td><td align="center">SF-36 (36 items)</td><td align="center">--</td><td align="center">--</td><td align="center">--</td><td align="center">--</td></tr><tr><td align="left">MS module</td><td align="center">18 items</td><td align="center">31 items</td><td align="center">9 scales</td><td align="center">50 items</td><td align="center">38 items</td><td align="center">29 items</td><td align="center">8 items</td></tr><tr><td align="left">People with MS involved in development</td><td align="center">No</td><td align="center">Yes</td><td align="center">--</td><td align="center">No</td><td align="center">Yes</td><td align="center">Yes</td><td align="center">Yes</td></tr><tr><td align="left">Versions</td><td align="center">US English [13]<break/>Italian [20]<break/>French [21]<break/>Canadian French [22]<break/>Japanese [23]</td><td align="center">US English [14]<break/>Portuguese [24]<break/></td><td align="center">US English [15]</td><td align="center">Hebrew [16]</td><td align="center">German [17]</td><td align="center">English [18]</td><td align="center">English [19]</td></tr><tr><td align="left">Reliability</td><td align="center">Alpha Test-retest [13,20&#x02013;23]</td><td align="center">Alpha [14,24]</td><td align="center">Alpha Test-retest [15]</td><td align="center">Alpha [16]</td><td align="center">Alpha Test-retest [17]</td><td align="center">Alpha Test-retest [18]</td><td align="center">Alpha Test-retest [19]</td></tr><tr><td align="left">Responsiveness</td><td align="center">RCT [25]<break/>RCT [26]</td><td align="center">--</td><td align="center">RCT [27]</td><td align="center">--</td><td align="center">RCT [28]</td><td align="center">Effect size [18]</td><td align="center">--</td></tr><tr><td align="left">Domains not assessed</td><td align="center">Vision</td><td align="center">Vision<break/>Bladder/ bowel<break/>Sexual function</td><td align="center">--</td><td align="center">--</td><td align="center">--</td><td align="center">Vision<break/>Sexual function</td><td align="center">Vision</td></tr><tr><td align="left">Time period assessed</td><td align="center">Past 4 weeks<break/>Current time</td><td align="center">Past week</td><td align="center">--</td><td align="center">Past week</td><td align="center">Past year<break/>Past 4 weeks<break/>Past week</td><td align="center">Past 2 weeks</td><td align="center">Past month</td></tr><tr><td align="left">Time to complete</td><td align="center">20 minutes</td><td align="center">20 minutes</td><td align="center">--</td><td align="center">--</td><td align="center">20 minutes</td><td align="center">--</td><td align="center">--</td></tr><tr><td align="left">Publications (no.)</td><td align="center">16</td><td align="center">10</td><td align="center">5</td><td align="center">1</td><td align="center">3</td><td align="center">7</td><td align="center">2</td></tr><tr><td align="left">Publication period</td><td align="center">1995&#x02013;2004</td><td align="center">1996&#x02013;2004</td><td align="center">1999&#x02013;2003</td><td align="center">2000</td><td align="center">2001&#x02013;2004</td><td align="center">2001&#x02013;2004</td><td align="center">2001</td></tr></tbody></table><table-wrap-foot><p>MSQOL-54 is the MS quality-of-life 54; FAMS is the Functional Assessment of MS; MSQLI is the MS Quality of Life; HAQUAMS is the Hamburg Quality of Life Questionnaire in MS; FACT-G is the Functional Assessment of Cancer Therapy, General version; LMSQoL is the Leeds MS Quality of Life. Alpha is Cronbach's coefficient alpha. RCT aspects of responsiveness assessed in randomized controlled trial.</p></table-wrap-foot></table-wrap></sec><sec><title>HRQOL and routine clinical practice</title><p>HRQOL studies in MS have drawn attention to the multiplicity of domains that may be compromised by the disease, and the effects of this compromise on ability to cope. As expected, people with MS, especially those with a progressive course, report reduced physical functioning compared to the general population [<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B29">29</xref>-<xref ref-type="bibr" rid="B31">31</xref>]; they are more likely to suffer fatigue [<xref ref-type="bibr" rid="B29">29</xref>,<xref ref-type="bibr" rid="B32">32</xref>] and depression [<xref ref-type="bibr" rid="B32">32</xref>,<xref ref-type="bibr" rid="B33">33</xref>] than the general population, and are also more likely to be unemployed [<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B30">30</xref>,<xref ref-type="bibr" rid="B31">31</xref>,<xref ref-type="bibr" rid="B34">34</xref>,<xref ref-type="bibr" rid="B35">35</xref>]. Unexpectedly, however, it has been reported that the importance attached to compromise in different HRQOL domains may vary considerably between MS sufferers and their neurologists [<xref ref-type="bibr" rid="B7">7</xref>].</p><p>The ultimate aim of measuring HRQOL is to provide a comprehensive assessment of patients' health status, to serve as a baseline from which to tailor interventions, pharmacological or otherwise, and assess their effectiveness, both in the clinical trial setting and in routine care. HRQOL instruments are expected to be of particular value in routine care, where they may improve the detection of disease aspects that would otherwise go unrecognised, help clinicians appreciate patient priorities particularly in terms of treatment goals, facilitate physician-patient communication, and promote shared decision making. In addition HRQOL data from clinical trials can provide information that clinicians can usefully discuss with their patients [<xref ref-type="bibr" rid="B36">36</xref>]. Unfortunately, although recent MS trials include some HRQOL assessment, there is no internationally agreed gold standard for conducting such assessment or reporting outcomes. HRQOL evaluations are not required as endpoints in MS trials by the European Agency for the Evaluation of Medicinal Products [<xref ref-type="bibr" rid="B37">37</xref>]. Even when HRQOL endpoints are included, data collection and reporting are often of poor quality [<xref ref-type="bibr" rid="B38">38</xref>] with the consequence that cost effectiveness issues, which HRQOL instruments can throw light on, such as preserved function, less work missed, and improved emotional well-being, are not analysed.</p></sec><sec><title>Literature survey</title><p>It appears that HRQOL instruments are little used in routine clinical approaches to people with MS. To address this issue, I searched MEDLINE (1966&#x02013;2004), the Cochrane Library (Issue 1, 2005) and the Cochrane MS Group trials register (2004) for studies that evaluated the efficacy of generic or MS-specific HRQOL instruments in clinical practice from the clinicians' or MS patients' perspective, also checking study references. Studies considering patient-reported outcomes other than HRQOL, and domain-specific measures were excluded.</p><p>I found only one study, a cross-sectional postal survey conducted in Canada, published in 2004 [<xref ref-type="bibr" rid="B39">39</xref>]. This study assessed MS sufferers' preferences regarding two generic instruments (the EuroQol EQ-5D and the SF-36), and an MS-specific instrument (MSQOL-54). Over 90% of 183 participants reported that EuroQol EQ-5D and the SF-36 were acceptable or very acceptable, and 85% did so for MSQOL-54. Surprisingly, over 75% of participants felt that a combination of the three instruments best described their HRQOL.</p><p>The reasons for lack of transfer of HRQOL assessment into clinical practice may be cultural, practical, or methodological [<xref ref-type="bibr" rid="B40">40</xref>-<xref ref-type="bibr" rid="B43">43</xref>]. With regard to cultural factors, patients generally welcome the opportunity to provide clinicians with information regarding their HRQOL [<xref ref-type="bibr" rid="B43">43</xref>]. That this is also the case for people with MS is suggested by high participation rates in most postal surveys assessing patient-reported health status [<xref ref-type="bibr" rid="B30">30</xref>,<xref ref-type="bibr" rid="B35">35</xref>,<xref ref-type="bibr" rid="B39">39</xref>,<xref ref-type="bibr" rid="B44">44</xref>], and by the good acceptability of HRQOL instruments [<xref ref-type="bibr" rid="B39">39</xref>]. By contrast, information on practicing clinicians' perceptions of the utility of HRQOL data is limited and conflicting: studies have uncovered a lack of knowledge of HRQOL as well as concerns that these instruments may be a covert means of assessing physicians' performance [<xref ref-type="bibr" rid="B45">45</xref>,<xref ref-type="bibr" rid="B46">46</xref>].</p><p>Practical considerations be particularly important in clinical settings, where data must be provided promptly and in an understandable manner to be of use. Instruments must be administered, processed, scored, stored and retrieved &#x02013; all of which have logistic and financial implications [<xref ref-type="bibr" rid="B47">47</xref>]. Most HRQOL instruments are lengthy and may be burdensome for patients and clinicians. For most existing instruments, the score is not immediately available, but needs to be calculated, while score interpretation may not be straightforward. For example a recently published study on transplant physicians found that 55% would be more likely to use HRQOL data if it were more comprehensible [<xref ref-type="bibr" rid="B48">48</xref>]. In the United States time spent gathering and interpreting HRQOL information as part of the clinical encounter is not built into reimbursement by third-party payers [<xref ref-type="bibr" rid="B49">49</xref>]. It is noteworthy, however, that questionnaire length seems not to be a drawback for people with MS since a combination of HRQOL instruments was preferred by over 75% of participants in the only study found [<xref ref-type="bibr" rid="B39">39</xref>].</p><p>Another factor limiting the dissemination of HRQOL tools in MS clinical practice is likely to be that too many instruments are available, and unlike EDSS, none has emerged as clearly superior to any other.</p></sec></sec><sec><title>Conclusion</title><p>Existing HRQOL tools for people with MS should be refined and their clinical validation pursued in the widest possible cultural context. More studies assessing instrument acceptability and preferences of clinicians and people with MS are also needed. It would be useful for example to implement computer-based technology (touch-screens and adaptive administration to reduce respondent burden by selecting pertinent items and omitting inappropriate ones) and other alternatives to traditional paper-and-pencil or interview methods, which should of course be evaluated for acceptability and reliability [<xref ref-type="bibr" rid="B48">48</xref>]. The objective is not to add HRQOL measurements to the chores of everyday practice, but to incorporate meaningful HRQOL instruments into the care process [<xref ref-type="bibr" rid="B50">50</xref>].</p><fig position="float" id="F1"><label>Figure 1</label><caption><p>Number of publications on HRQOL in people with MS between 1992 and 2004. Blue bars indicate all studies on HRQOL; light blue bars indicate studies employing MS-specific instruments. Studies considering patient-reported outcomes other than HRQOL, or domain-specific measures are excluded.</p></caption><graphic xlink:href="1477-7525-3-16-1"/></fig></sec></body><back><ack><sec><title>Acknowledgements</title><p>I am indebted to Dr. Barbara Vickrey and Dr. Christoph Heesen for their helpful suggestions for improving the manuscript. Thanks are also due to Dr. Maura Moggia, trial search coordinator of the Cochrane MS Group, for providing the search strategy, and to Mrs. Giusi Ferrari for retrieving the studies, and to Don Ward for help with the English.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Compston</surname><given-names>A</given-names></name></person-group><article-title>Genetic epidemiology of multiple sclerosis</article-title><source>J Neurol Neurosurg Psychiatry</source><year>1997</year><volume>62</volume><fpage>553</fpage><lpage>561</lpage><pub-id pub-id-type="pmid">9219738</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kurtzke</surname><given-names>JF</given-names></name></person-group><article-title>Geography in multiple sclerosis</article-title><source>J Neurol</source><year>1977</year><volume>215</volume><fpage>1</fpage><lpage>26</lpage><pub-id pub-id-type="pmid">67196</pub-id><pub-id pub-id-type="doi">10.1007/BF00312546</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sadovnick</surname><given-names>AD</given-names></name><name><surname>Ebers</surname><given-names>GC</given-names></name></person-group><article-title>Epidemiology of multiple sclerosis: a critical overview</article-title><source>Can J Neurol Sci</source><year>1993</year><volume>20</volume><fpage>17</fpage><lpage>29</lpage><pub-id pub-id-type="pmid">8467424</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pittock</surname><given-names>SJ</given-names></name><name><surname>McClelland</surname><given-names>RL</given-names></name><name><surname>Mayr</surname><given-names>WT</given-names></name><name><surname>Jorgesten</surname><given-names>NW</given-names></name><name><surname>Weinshenker</surname><given-names>BG</given-names></name><name><surname>Noseworthy</surname><given-names>J</given-names></name><name><surname>Rodriguez</surname><given-names>M</given-names></name></person-group><article-title>Clinical implications of benign multiple sclerosis: A 20-year population-based follow-up study</article-title><source>Ann Neurol</source><year>2004</year><volume>56</volume><fpage>303</fpage><lpage>306</lpage><pub-id pub-id-type="pmid">15293286</pub-id><pub-id pub-id-type="doi">10.1002/ana.20197</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Filippini</surname><given-names>G</given-names></name><name><surname>Munari</surname><given-names>L</given-names></name><name><surname>Incorvaia</surname><given-names>B</given-names></name></person-group><article-title>Interferons in relapsing remitting multiple sclerosis: a systematic review</article-title><source>Lancet</source><year>2003</year><volume>361</volume><fpage>545</fpage><lpage>552</lpage><pub-id pub-id-type="pmid">12598138</pub-id><pub-id pub-id-type="doi">10.1016/S0140-6736(03)12512-3</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kurtzke</surname><given-names>JF</given-names></name></person-group><article-title>Rating neurologic impairment in multiple sclerosis: an expanded disability status scale</article-title><source>Neurology</source><year>1983</year><volume>33</volume><fpage>1444</fpage><lpage>1452</lpage><pub-id pub-id-type="pmid">6685237</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rothwell</surname><given-names>PM</given-names></name><name><surname>McDowell</surname><given-names>Z</given-names></name><name><surname>Wong</surname><given-names>CK</given-names></name><name><surname>Dorman</surname><given-names>PJ</given-names></name></person-group><article-title>Doctors and patients don't agree: cross sectional study of patients and doctors perceptions and assessments of disability in multiple sclerosis</article-title><source>BMJ</source><year>1997</year><volume>314</volume><fpage>1580</fpage><lpage>1583</lpage><pub-id pub-id-type="pmid">9169401</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aronson</surname><given-names>KJ</given-names></name></person-group><article-title>Quality of life among persons with multiple sclerosis and their caregivers</article-title><source>Neurology</source><year>1997</year><volume>48</volume><fpage>74</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">9008497</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brunet</surname><given-names>DG</given-names></name><name><surname>Hopman</surname><given-names>WM</given-names></name><name><surname>Singer</surname><given-names>MA</given-names></name><name><surname>Edgar</surname><given-names>CM</given-names></name><name><surname>MacKenzie</surname><given-names>TA</given-names></name></person-group><article-title>Measurement of health-related quality of life in multiple sclerosis patients</article-title><source>Can J Neurol Sci</source><year>1996</year><volume>23</volume><fpage>99</fpage><lpage>103</lpage><pub-id pub-id-type="pmid">8738920</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><article-title>Burden of illness of multiple sclerosis: Part II: Quality of life. The Canadian Burden of Illness Study Group</article-title><source>Can J Neurol Sci</source><year>1998</year><volume>25</volume><fpage>31</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">9532278</pub-id></citation></ref><ref id="B11"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Pfennings</surname><given-names>LEMA</given-names></name><name><surname>Cohen</surname><given-names>L</given-names></name><name><surname>Van der Ploeg</surname><given-names>HM</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Thompson AJ, Polman C, Hohlfeld R</surname></name></person-group><article-title>Assessing the quality of life in patients with multiple sclerosis</article-title><source>Multiple sclerosis: clinical changes and controversies</source><year>1997</year><publisher-name>London: Martin Dunitz</publisher-name></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lintern</surname><given-names>TC</given-names></name><name><surname>Beaumont</surname><given-names>G</given-names></name><name><surname>Kenealy</surname><given-names>PM</given-names></name><name><surname>Murrell</surname><given-names>RC</given-names></name></person-group><article-title>Quality of life (QoL) in severely disabled multiple sclerosis patients: Comparison of three QoL measures using multidimensional scaling</article-title><source>Qual Life Res</source><year>2001</year><volume>10</volume><fpage>371</fpage><lpage>378</lpage><pub-id pub-id-type="pmid">11763249</pub-id><pub-id pub-id-type="doi">10.1023/A:1012219504134</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vickrey</surname><given-names>BG</given-names></name><name><surname>Hays</surname><given-names>RD</given-names></name><name><surname>Harooni</surname><given-names>R</given-names></name><name><surname>Myers</surname><given-names>LW</given-names></name><name><surname>Ellison</surname><given-names>GW</given-names></name></person-group><article-title>A health-related quality of life measure for multiple sclerosis</article-title><source>Qual Life Res</source><year>1995</year><volume>4</volume><fpage>187</fpage><lpage>206</lpage><pub-id pub-id-type="pmid">7613530</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cella</surname><given-names>DF</given-names></name><name><surname>Dineen</surname><given-names>MA</given-names></name><name><surname>Arnason</surname><given-names>B</given-names></name><name><surname>Reder</surname><given-names>A</given-names></name><name><surname>Webster</surname><given-names>KA</given-names></name><name><surname>karabatsos</surname><given-names>G</given-names></name><name><surname>Chang</surname><given-names>C</given-names></name><name><surname>Lloyd</surname><given-names>S</given-names></name><name><surname>Steward</surname><given-names>J</given-names></name><name><surname>Stefoski</surname><given-names>D</given-names></name></person-group><article-title>Validation of the Functional Assessment of Multiple Sclerosis quality of life instrument</article-title><source>Neurology</source><year>1996</year><volume>47</volume><fpage>129</fpage><lpage>139</lpage><pub-id pub-id-type="pmid">8710066</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fischer</surname><given-names>JS</given-names></name><name><surname>LaRocca</surname><given-names>NG</given-names></name><name><surname>Miller</surname><given-names>DM</given-names></name><name><surname>Ritvo</surname><given-names>PG</given-names></name><name><surname>Andrews</surname><given-names>H</given-names></name><name><surname>Paty</surname><given-names>D</given-names></name></person-group><article-title>Recent developments in the assessment of quality of life in multiple sclerosis (MS)</article-title><source>Mult Scler</source><year>1999</year><volume>5</volume><fpage>251</fpage><lpage>259</lpage><pub-id pub-id-type="pmid">10467384</pub-id><pub-id pub-id-type="doi">10.1191/135245899678846177</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rotstein</surname><given-names>Z</given-names></name><name><surname>Barak</surname><given-names>Y</given-names></name><name><surname>Noy</surname><given-names>S</given-names></name><name><surname>Achiron</surname><given-names>A</given-names></name></person-group><article-title>Quality of life in multiple sclerosis: development and validation of the "RAYS" scale and comparison with the SF-36</article-title><source>Int J Qual Health Care</source><year>2000</year><volume>12</volume><fpage>511</fpage><lpage>517</lpage><pub-id pub-id-type="pmid">11202605</pub-id><pub-id pub-id-type="doi">10.1093/intqhc/12.6.511</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gold</surname><given-names>SM</given-names></name><name><surname>Heesen</surname><given-names>C</given-names></name><name><surname>Schulz</surname><given-names>H</given-names></name><name><surname>Guder</surname><given-names>U</given-names></name><name><surname>Monch</surname><given-names>A</given-names></name><name><surname>Gbadamosi</surname><given-names>J</given-names></name><name><surname>Buhmann</surname><given-names>C</given-names></name><name><surname>Schulz</surname><given-names>KH</given-names></name></person-group><article-title>Disease-specific quality of life instruments in multiple sclerosis: validation of the Hamburg Quality of Life Questionnaire in multiple sclerosis (HAQUAMS)</article-title><source>Mult Scler</source><year>2001</year><volume>7</volume><fpage>119</fpage><lpage>130</lpage><pub-id pub-id-type="pmid">11424632</pub-id><pub-id pub-id-type="doi">10.1191/135245801678227649</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hobart</surname><given-names>JC</given-names></name><name><surname>Lamping</surname><given-names>DL</given-names></name><name><surname>Fitzpatrick</surname><given-names>R</given-names></name><name><surname>Riazi</surname><given-names>A</given-names></name><name><surname>Thompson</surname><given-names>A</given-names></name></person-group><article-title>The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure</article-title><source>Brain</source><year>2001</year><volume>124</volume><fpage>962</fpage><lpage>973</lpage><pub-id pub-id-type="pmid">11335698</pub-id><pub-id pub-id-type="doi">10.1093/brain/124.5.962</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ford</surname><given-names>HL</given-names></name><name><surname>Gerry</surname><given-names>E</given-names></name><name><surname>Tennant</surname><given-names>A</given-names></name><name><surname>Whalley</surname><given-names>D</given-names></name><name><surname>Haigh</surname><given-names>R</given-names></name><name><surname>Johnson</surname><given-names>MH</given-names></name></person-group><article-title>Developing a disease-specific quality of life measure for people with multiple sclerosis</article-title><source>Clin Rehabil</source><year>2001</year><volume>15</volume><fpage>247</fpage><lpage>258</lpage><pub-id pub-id-type="pmid">11386394</pub-id><pub-id pub-id-type="doi">10.1191/026921501673658108</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Solari</surname><given-names>A</given-names></name><name><surname>Filippini</surname><given-names>G</given-names></name><name><surname>Mendozzi</surname><given-names>L</given-names></name><name><surname>Grezzi</surname><given-names>A</given-names></name><name><surname>Cifani</surname><given-names>S</given-names></name><name><surname>Barbieri</surname><given-names>E</given-names></name><name><surname>Baldini</surname><given-names>S</given-names></name><name><surname>Salmeggi</surname><given-names>A</given-names></name><name><surname>LaMantia</surname><given-names>L</given-names></name><name><surname>Farinotti</surname><given-names>M</given-names></name><name><surname>Caputo</surname><given-names>D</given-names></name><name><surname>Mosconi</surname><given-names>P</given-names></name></person-group><article-title>Validation of Italian multiple sclerosis quality of life 54 questionnaire</article-title><source>J Neurol Neurosurg Psychiatry</source><year>1999</year><volume>67</volume><fpage>158</fpage><lpage>162</lpage><pub-id pub-id-type="pmid">10406981</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vernay</surname><given-names>D</given-names></name><name><surname>Gerbaud</surname><given-names>L</given-names></name><name><surname>Biolay</surname><given-names>S</given-names></name><name><surname>Coste</surname><given-names>J</given-names></name><name><surname>Debourse</surname><given-names>J</given-names></name><name><surname>Aufauvre</surname><given-names>D</given-names></name><name><surname>Beneton</surname><given-names>C</given-names></name><name><surname>Colamarino</surname><given-names>R</given-names></name><name><surname>Glandier</surname><given-names>PY</given-names></name><name><surname>Dordain</surname><given-names>G</given-names></name><name><surname>Clavelou</surname><given-names>P</given-names></name></person-group><article-title>Quality of life and multiple sclerosis: validation of the French version of the self-questionnaire (SEP-59)</article-title><source>Rev Neur</source><year>2000</year><volume>156</volume><fpage>247</fpage><lpage>263</lpage></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Acquadro</surname><given-names>C</given-names></name><name><surname>Lafortune</surname><given-names>L</given-names></name><name><surname>Mear</surname><given-names>I</given-names></name></person-group><article-title>Quality of life in multiple sclerosis: translation in French Canadian of the MSQoL-54</article-title><source>Health Qual Life Outcomes</source><year>2003</year><volume>1</volume><fpage>70</fpage><pub-id pub-id-type="pmid">14636427</pub-id><pub-id pub-id-type="doi">10.1186/1477-7525-1-70</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yamamoto</surname><given-names>T</given-names></name><name><surname>Ogata</surname><given-names>K</given-names></name><name><surname>Katagishi</surname><given-names>M</given-names></name><name><surname>Shimizu</surname><given-names>H</given-names></name><name><surname>Ogawa</surname><given-names>M</given-names></name><name><surname>Yamamura</surname><given-names>T</given-names></name><name><surname>Kawai</surname><given-names>M</given-names></name></person-group><article-title>Validation of the Japanese-translated version Multiple Sclerosis Quality of Life-54 instrument</article-title><source>Rinsho Shinkeigaku</source><year>2004</year><volume>44</volume><fpage>417</fpage><lpage>421</lpage><pub-id pub-id-type="pmid">15384701</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mendes</surname><given-names>MF</given-names></name><name><surname>Balsimelli</surname><given-names>S</given-names></name><name><surname>Stangehaus</surname><given-names>G</given-names></name><name><surname>Tilbery</surname><given-names>CP</given-names></name></person-group><article-title>Validation of the functional assessment of multiple sclerosis quality of life instrument in a Portuguese language</article-title><source>Arq Neuropsiquiatr</source><year>2004</year><volume>62</volume><fpage>108</fpage><lpage>113</lpage><pub-id pub-id-type="pmid">15122443</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lincoln</surname><given-names>NB</given-names></name><name><surname>Dent</surname><given-names>A</given-names></name><name><surname>Harding</surname><given-names>J</given-names></name><name><surname>Weyman</surname><given-names>N</given-names></name><name><surname>Nicholl</surname><given-names>C</given-names></name><name><surname>Blumhardt</surname><given-names>LD</given-names></name><name><surname>Playford</surname><given-names>ED</given-names></name></person-group><article-title>Evaluation of cognitive assessment and cognitive intervention for people with multiple sclerosis</article-title><source>J Neurol Neurosurg Psychiatry</source><year>2002</year><volume>72</volume><fpage>93</fpage><lpage>98</lpage><pub-id pub-id-type="pmid">11784832</pub-id><pub-id pub-id-type="doi">10.1136/jnnp.72.1.93</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Solari</surname><given-names>A</given-names></name><name><surname>Motta</surname><given-names>A</given-names></name><name><surname>Mendozzi</surname><given-names>L</given-names></name><name><surname>Pucci</surname><given-names>E</given-names></name><name><surname>Forni</surname><given-names>M</given-names></name><name><surname>Mancardi</surname><given-names>G</given-names></name><name><surname>Pozzilli</surname><given-names>C</given-names></name></person-group><article-title>Computer-aided retraining of memory and attention in people with multiple sclerosis: a randomized, double-blind controlled trial</article-title><source>J Neurol Sci</source><year>2004</year><volume>222</volume><fpage>99</fpage><lpage>104</lpage><pub-id pub-id-type="pmid">15240203</pub-id><pub-id pub-id-type="doi">10.1016/j.jns.2004.04.027</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>JA</given-names></name><name><surname>Cutter</surname><given-names>GR</given-names></name><name><surname>Fischer</surname><given-names>JS</given-names></name><name><surname>Goodman</surname><given-names>AD</given-names></name><name><surname>Heidenreich</surname><given-names>FR</given-names></name><name><surname>Kooijmans</surname><given-names>MF</given-names></name><name><surname>Sandrock</surname><given-names>AW</given-names></name><name><surname>Rudick</surname><given-names>RA</given-names></name><name><surname>Simon</surname><given-names>JH</given-names></name><name><surname>Simonian</surname><given-names>NA</given-names></name><name><surname>Tsao</surname><given-names>EC</given-names></name><name><surname>Whitaker</surname><given-names>JN</given-names></name></person-group><article-title>Benefit of interferon &#x003b2;-1a on MSFC progression in secondary progressive MS</article-title><source>Neurology</source><year>2002</year><volume>59</volume><fpage>679</fpage><lpage>687</lpage><pub-id pub-id-type="pmid">12221157</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schulz</surname><given-names>KH</given-names></name><name><surname>Gold</surname><given-names>SM</given-names></name><name><surname>Witte</surname><given-names>J</given-names></name><name><surname>Bartsch</surname><given-names>K</given-names></name><name><surname>Lang</surname><given-names>UE</given-names></name><name><surname>Hellweg</surname><given-names>R</given-names></name><name><surname>Reer</surname><given-names>R</given-names></name><name><surname>Braumann</surname><given-names>KM</given-names></name><name><surname>Heesen</surname><given-names>C</given-names></name></person-group><article-title>Impact of aerobic training on immune-endocrine parameters, neutrophic factors, quality of life and coordinative function in multiple sclerosis</article-title><source>J Neurol Sci</source><year>2004</year><volume>225</volume><fpage>11</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">15465080</pub-id><pub-id pub-id-type="doi">10.1016/j.jns.2004.06.009</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lobentanz</surname><given-names>IS</given-names></name><name><surname>Asenbaum</surname><given-names>S</given-names></name><name><surname>Vass</surname><given-names>K</given-names></name><name><surname>Sauter</surname><given-names>C</given-names></name><name><surname>Kl&#x000f6;sch</surname><given-names>G</given-names></name><name><surname>Kollegger</surname><given-names>H</given-names></name><name><surname>Kristoferitsch</surname><given-names>W</given-names></name><name><surname>Zeitlhofer</surname><given-names>J</given-names></name></person-group><article-title>Factors influencing quality of life in multiple sclerosis patients: disability, depressive mood, fatigue and sleep quality</article-title><source>Acta Neurol Scand</source><year>2004</year><volume>110</volume><fpage>6</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">15180801</pub-id><pub-id pub-id-type="doi">10.1111/j.1600-0404.2004.00257.x</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Solari</surname><given-names>A</given-names></name><name><surname>Radice</surname><given-names>D</given-names></name></person-group><article-title>Health status of people with multiple sclerosis: a community mail survey</article-title><source>Neurol Sci</source><year>2001</year><volume>22</volume><fpage>307</fpage><lpage>315</lpage><pub-id pub-id-type="pmid">11808854</pub-id><pub-id pub-id-type="doi">10.1007/s10072-001-8173-8</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Henriksson</surname><given-names>F</given-names></name><name><surname>Fredrikson</surname><given-names>S</given-names></name><name><surname>Masterman</surname><given-names>T</given-names></name><name><surname>J&#x000f6;nsson</surname><given-names/></name></person-group><article-title>Costs, quality of life and disease severity in multiple sclerosis: a cross-sectional study in Sweden</article-title><source>Eur J Neurol</source><year>2001</year><volume>8</volume><fpage>27</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">11509078</pub-id><pub-id pub-id-type="doi">10.1046/j.1468-1331.2001.00169.x</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Amato</surname><given-names>MP</given-names></name><name><surname>Ponziani</surname><given-names>G</given-names></name><name><surname>Rossi</surname><given-names>F</given-names></name><name><surname>Liedl</surname><given-names>CL</given-names></name><name><surname>Stefanile</surname><given-names>C</given-names></name><name><surname>Rossi</surname><given-names>L</given-names></name></person-group><article-title>Quality of life in multiple sclerosis: the impact of depression, fatigue, and disability</article-title><source>Mult Scler</source><year>2001</year><volume>7</volume><fpage>340</fpage><lpage>344</lpage><pub-id pub-id-type="pmid">11724451</pub-id><pub-id pub-id-type="doi">10.1191/135245801681138059</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>JL</given-names></name><name><surname>Reimer</surname><given-names>MA</given-names></name><name><surname>Metz</surname><given-names>LM</given-names></name><name><surname>Patten</surname><given-names>SB</given-names></name></person-group><article-title>Major depression and quality of life in individuals with multiple sclerosis</article-title><source>Int J Psychiatry Med</source><year>2000</year><volume>30</volume><fpage>309</fpage><lpage>317</lpage><pub-id pub-id-type="pmid">11308035</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gr&#x000f8;nning</surname><given-names>M</given-names></name><name><surname>Hannisdal</surname><given-names>E</given-names></name><name><surname>Mellgren</surname><given-names>SI</given-names></name></person-group><article-title>Multivariate analyses of factors associated with unemployment in people with multiple sclerosis</article-title><source>J Neurol Neurosurg Psychiatry</source><year>1990</year><volume>53</volume><fpage>388</fpage><lpage>390</lpage><pub-id pub-id-type="pmid">2351967</pub-id></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ford</surname><given-names>HL</given-names></name><name><surname>Gerry</surname><given-names>E</given-names></name><name><surname>Johnson</surname><given-names>MH</given-names></name><name><surname>Tennant</surname><given-names>A</given-names></name></person-group><article-title>Health status and quality of life measure of people with multiple sclerosis</article-title><source>Disabil Rehabil</source><year>2001</year><volume>23</volume><fpage>516</fpage><lpage>521</lpage><pub-id pub-id-type="pmid">11432648</pub-id><pub-id pub-id-type="doi">10.1080/09638280010022090</pub-id></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vickrey</surname><given-names>BG</given-names></name></person-group><article-title>Getting oriented to patient-oriented outcomes</article-title><source>Neurology</source><year>1999</year><volume>53</volume><fpage>662</fpage><lpage>663</lpage><pub-id pub-id-type="pmid">10489021</pub-id></citation></ref><ref id="B37"><citation citation-type="other"><article-title>Note for guidance on clinical investigation of medicinal products for the treatment of multiple sclerosis</article-title><ext-link ext-link-type="uri" xlink:href="http://www.emea.eu.int/pdfs/human/ewp/056198en.pdf"/><comment>last accessed March 2005</comment></citation></ref><ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moher</surname><given-names>D</given-names></name><name><surname>Schulz</surname><given-names>KF</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name></person-group><article-title>The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials</article-title><source>Lancet</source><year>2001</year><volume>357</volume><fpage>1191</fpage><lpage>1194</lpage><pub-id pub-id-type="pmid">11323066</pub-id><pub-id pub-id-type="doi">10.1016/S0140-6736(00)04337-3</pub-id></citation></ref><ref id="B39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moore</surname><given-names>F</given-names></name><name><surname>Wolfson</surname><given-names>C</given-names></name><name><surname>Alexandrov</surname><given-names>L</given-names></name><name><surname>Lapierre</surname><given-names>Y</given-names></name></person-group><article-title>Do general and multiple sclerosis- specific quality of life instruments differ?</article-title><source>Can J Neurol Sci</source><year>2004</year><volume>31</volume><fpage>64</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">15038473</pub-id></citation></ref><ref id="B40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Deyo</surname><given-names>RA</given-names></name><name><surname>Patrick</surname><given-names>DL</given-names></name></person-group><article-title>Barriers to the use of health status measures in clinical investigation, patient care, and policy research</article-title><source>Med Care</source><year>1989</year><volume>27</volume><fpage>S252</fpage><lpage>S268</lpage></citation></ref><ref id="B41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McHorney</surname><given-names>CA</given-names></name><name><surname>Taylor</surname><given-names>AR</given-names></name></person-group><article-title>Individual-patient monitoring in clinical practice: are available health status surveys adequate?</article-title><source>Qual Life Res</source><year>1995</year><volume>4</volume><fpage>293</fpage><lpage>307</lpage><pub-id pub-id-type="pmid">7550178</pub-id></citation></ref><ref id="B42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rubenstein</surname><given-names>LV</given-names></name><name><surname>McCoy</surname><given-names>JM</given-names></name><name><surname>Cope</surname><given-names>DW</given-names></name><name><surname>Barrett</surname><given-names>PA</given-names></name><name><surname>Hirsch</surname><given-names>SH</given-names></name><name><surname>Messer</surname><given-names>KS</given-names></name><name><surname>Young</surname><given-names>RT</given-names></name></person-group><article-title>Improving patient quality of life with feedback to physicians about functional status</article-title><source>J Gen Intern Med</source><year>1995</year><volume>10</volume><fpage>607</fpage><lpage>614</lpage><pub-id pub-id-type="pmid">8583263</pub-id></citation></ref><ref id="B43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nelson</surname><given-names>EC</given-names></name><name><surname>Landgraf</surname><given-names>JM</given-names></name><name><surname>Hays</surname><given-names>RD</given-names></name><name><surname>Wasson</surname><given-names>JH</given-names></name><name><surname>Kirk</surname><given-names>JW</given-names></name></person-group><article-title>The functional status of patients: how can it be measured in physician's offices?</article-title><source>Med Care</source><year>1990</year><volume>28</volume><fpage>1111</fpage><lpage>1126</lpage><pub-id pub-id-type="pmid">2250496</pub-id></citation></ref><ref id="B44"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Somerset</surname><given-names>M</given-names></name><name><surname>Campbell</surname><given-names>R</given-names></name><name><surname>Sharp</surname><given-names>DJ</given-names></name><name><surname>Peters</surname><given-names>T</given-names></name></person-group><article-title>What do people with MS want and expect from health-care services?</article-title><source>Health Expectations</source><year>2001</year><volume>4</volume><fpage>29</fpage><lpage>37</lpage><pub-id pub-id-type="pmid">11286597</pub-id><pub-id pub-id-type="doi">10.1046/j.1369-6513.2001.00111.x</pub-id></citation></ref><ref id="B45"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kazis</surname><given-names>LE</given-names></name><name><surname>Callahan</surname><given-names>LF</given-names></name><name><surname>Meenan</surname><given-names>RF</given-names></name><name><surname>Pincus</surname><given-names>TSO</given-names></name></person-group><article-title>Health status reports in the care of patients with rheumatoid arthritis</article-title><source>J Clin Epidemiol</source><year>1990</year><volume>43</volume><fpage>1243</fpage><lpage>1253</lpage><pub-id pub-id-type="pmid">2243259</pub-id><pub-id pub-id-type="doi">10.1016/0895-4356(90)90025-K</pub-id></citation></ref><ref id="B46"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wagner</surname><given-names>AK</given-names></name><name><surname>Ehrenberg</surname><given-names>BL</given-names></name><name><surname>Tran</surname><given-names>TA</given-names></name><name><surname>Bungay</surname><given-names>KM</given-names></name><name><surname>Cynn</surname><given-names>DJ</given-names></name><name><surname>Rogers</surname><given-names>WH</given-names></name></person-group><article-title>Patient-based health status measurement in clinical practice: a study of its impact on epilepsy patients' care</article-title><source>Qual Life Res</source><year>1997</year><volume>6</volume><fpage>329</fpage><lpage>341</lpage><pub-id pub-id-type="pmid">9248315</pub-id><pub-id pub-id-type="doi">10.1023/A:1018479209369</pub-id></citation></ref><ref id="B47"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gilbody</surname><given-names>SM</given-names></name><name><surname>House</surname><given-names>AO</given-names></name><name><surname>Sheldon</surname><given-names>TA</given-names></name></person-group><article-title>Psychiatrists in the UK do not use outcomes measures. National survey</article-title><source>Br J Psychiatry</source><year>2002</year><volume>180</volume><fpage>101</fpage><lpage>103</lpage><pub-id pub-id-type="pmid">11823316</pub-id><pub-id pub-id-type="doi">10.1192/bjp.180.2.101</pub-id></citation></ref><ref id="B48"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>SJ</given-names></name><name><surname>Joffe</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>HT</given-names></name><name><surname>Socie</surname><given-names>G</given-names></name><name><surname>Gilman</surname><given-names>AL</given-names></name><name><surname>Wingard</surname><given-names>JR</given-names></name><name><surname>Horowitz</surname><given-names>MM</given-names></name><name><surname>Cella</surname><given-names>D</given-names></name><name><surname>Syrjala</surname><given-names>KL</given-names></name></person-group><article-title>Physicians' attitudes about quality of life issues in haematopoietic stem cell transplantation</article-title><source>Blood</source><year>2004</year><volume>104</volume><fpage>2194</fpage><lpage>2200</lpage><pub-id pub-id-type="pmid">15198954</pub-id><pub-id pub-id-type="doi">10.1182/blood-2003-07-2430</pub-id></citation></ref><ref id="B49"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Donaldson</surname><given-names>MS</given-names></name></person-group><article-title>Tacking stock of health-related quality-of-life measurement in oncology practice in the United States</article-title><source>J Natl Cancer Inst Monogr</source><year>2004</year><volume>33</volume><fpage>155</fpage><lpage>167</lpage><pub-id pub-id-type="pmid">15504926</pub-id><pub-id pub-id-type="doi">10.1093/jncimonographs/lgh017</pub-id></citation></ref><ref id="B50"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fitzpatrick</surname><given-names>R</given-names></name><name><surname>Fletcher</surname><given-names>A</given-names></name><name><surname>Gore</surname><given-names>S</given-names></name><name><surname>Jones</surname><given-names>D</given-names></name><name><surname>Spiegelhalter</surname><given-names>D</given-names></name><name><surname>Cox</surname><given-names>D</given-names></name></person-group><article-title>Quality of life measures in health care. I: Applications and issues in assessment</article-title><source>BMJ</source><year>1992</year><volume>305</volume><fpage>1074</fpage><lpage>1077</lpage><pub-id pub-id-type="pmid">1467690</pub-id></citation></ref></ref-list></back></article>



